Some shift to save money in response to CVS Caremark restrictions; others appeal for Zepbound coverage, citing better weight-loss results By Peter Loftus Follow Updated July 27, 2025 10:57 am ET ...

Patients taking the GLP-1 weight loss drug Zepbound face mandatory switch to Wegovy after CVS Caremark removed the Eli Lilly medication from its preferred coverage list, citing rising costs.

Cigna's Evernorth is signaling that it will expand its GLP-1 medication offerings through the creation of Evernorth EnReachRx, a new patient support model for pharmacies that want to provide enhanced ...

When Zepbound, Eli Lilly's highly anticipated weight loss drug, hit the market a year and a half ago, it marked a turning point for the accessibility of weight loss drugs. Since then, Zepbound ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

In interviews, patients said that they had specifically sought out Zepbound and didn’t want to switch. “I chose Zepbound with my doctor,” said Carl Houde, 49, of Saugus, Mass.

Zepbound and Wegovy are approved for weight loss and weight management in certain adults. Other drugs, such as Rybelsus, Ozempic, and Mounjaro, are not approved for this purpose but may be ...

Trizepatide (Zepbound), on the other hand, mimics two different hormones — GLP-1 and GIP — both of which the body produces after one eats. GIP bolsters how the body processes sugar and fat.